Likewise, GRPR expression is also not unique to the prostate nor to prostate cancer; the high absorbed pancreatic dose and diffuse low uptake throughout the gastrointestinal tract constitute a serious concern for therapy [21,135]. This evidence concerns the gene GRPR and prostate carcinoma.